Drs. Crawford and Hou provide an important clinical introduction to a novel class of hormonal agents that have been under development for several decades for the treatment of advanced and metastatic prostate cancer.
Marc B. Garnick, MD
Advertisement
Articles by Marc B. Garnick, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
ASCO 2026: The Presentations That May Shape The Future of Multiple Myeloma
2
Durvalumab Plus BCG Earns FDA Approval For High-Risk NMIBC
3
What Are The Top Lymphoma Abstracts at ASCO 2026?
4
ASCO 2026: Key Genitourinary Oncology Trials to Watch For
5